60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Friday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $1.05 on Friday. The company has a market capitalization of $2.41 million, a PE ratio of -0.10 and a beta of 4.40. The company has a 50-day simple moving average of $1.19 and a two-hundred day simple moving average of $0.98. 60 Degrees Pharmaceuticals has a one year low of $0.70 and a one year high of $13.20.

Insider Activity at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow acquired 35,823 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the acquisition, the chief executive officer now owns 94,580 shares in the company, valued at approximately $120,116.60. This trade represents a 60.97 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 66,372 shares of company stock valued at $82,410 over the last 90 days. Insiders own 10.27% of the company’s stock.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.